pharma · Cystic Adenomatoid Malformation of Lung, Congenital
Lei Xiaoming
Lei Xiaoming is a pharma organization headquartered in CN. Primary therapeutic focus areas include Cystic Adenomatoid Malformation of Lung, Congenital. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Ropivacaine
Unknown · small molecule · Cystic Adenomatoid Malformation of Lung, Congenital
Ropivacaine for Cystic Adenomatoid Malformation of Lung, Congenital is a Unknown program (small_molecule) at Lei Xiaoming with 1 ClinicalTrials.gov record(s).
Internal code 2024-015
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lei Xiaoming
- Phase
- Unknown
- Modality
- small_molecule
- Indication
- Cystic Adenomatoid Malformation of Lung, Congenital
- Status
- completed
- Trials
- 1